Our main research area is the “Health and Quality of Life in Patients with Early Age Onset Cancer”. Our currently ongoing projects (MiLLI-C, Fysakt, PACS, Syöpäsydän) aim to recognition and alleviation of adverse effects of cancer therapies. Milli-C evaluates immune reconstitution and metabolic adverse effects (like obesity) in relation to changes in the gut microbiota. Syöpäsydän is a nation-wide registry-based study on cardiovascular morbidity and mortality following cancer treatment, and Fysakt is an international study on physical activity after childhood cancer. PACS is a Nordic study on short and long-term consequences of pregnancy-associated cancer in women and their offspring, with collaborators from Denmark, Sweden and Norway. Furthermore, a local project called Digital tools in detecting late-effects in adult childhood cancer survivors has started in 2018 at our late-effect clinic. A new approach will be a project on genetics of cancer predisposition and drugs used in cancer treatments.

Docent Lähteenmäki is also the PI for a Nordic study on epidemiology, biology, treatment, and survival of children with cancer and severe hematological diseases (NOPHO-CARE) funded by the Swedish Childhood Cancer Foundation.

Senior scientist: Docent, MD, PhD Päivi Lähteenmäki

Own research projects: MD, PhD Anu Huurre, MD, PhD Liisa Järvelä, MD, PhD Marika Grönroos, MD, PhD Laura Korhonen, MD, PhD Linnea Schuez-Havupalo